Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13684196 | 0.93 | MEN1 (0.32) | THRBTGFBR1MAPK14KDM4EPRMT1 | |
| SCHEMBL16920699 | 0.91 | MEN1 (0.35) | THRBTGFBR1PRMT1PRMT6 | |
| SCHEMBL24744542 | 0.78 | THRB (0.33) | THRBTGFBR1MAPK14 | |
| SCHEMBL110500 | 0.78 | L3MBTL1 (0.42) | THRBTGFBR1MAPK14L3MBTL1 | |
| SCHEMBL26937985 | 0.75 | KDM5B (0.33) | THRBTGFBR1MAPK14 | |
| SCHEMBL26340803 | 0.75 | THRB (0.32) | THRBTGFBR1MAPK14 | |
| SCHEMBL22275416 | 0.74 | PRMT1 (0.35) | THRBTGFBR1MAPK14PRMT1PRMT6 | |
| SCHEMBL15918967 | 0.72 | — | — | |
| SCHEMBL38665339 | 0.72 | ALDH1A1 (0.32) | THRBTGFBR1KDM4EPRMT1PRMT6 | |
| SCHEMBL23664362 | 0.72 | MEN1 (0.31) | THRBTGFBR1PRMT1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2023072273-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | 先声再明医药有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2021126316-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3470409-B1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2020-02-04 | — | — | US | disclosed |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | GENFLEET THERAPEUTICS SHANGHAI INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3470409-A1 | BENZOTRIAZOLE-DERIVED AND UNSATURATED AMIDE COMPOUND USED AS TGF- R1 INHIBITOR | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2019-04-17 | — | — | EP | disclosed |
| US-9828389-B2 | Tetrazolinone compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9554576-B2 | Tetrazolinone compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160183529-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9314023-B2 | Tetrazolinone compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150223460-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150203511-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | YOUNGMAN MICHAEL | 2009-07-23 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548883-B2 | Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor | TGFBR1, TGFBR2, TGFB1 | THRB 75/4885TGFBR1 1/4885MAPK14 656/4885 |
| US-20150223460-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | CYCS, MT-CO3, OXER1 | THRB 1061/4885TGFBR1 2685/4885MAPK14 2223/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | THRB 2/4885TGFBR1 498/4885MAPK14 2403/4885 |
| US-20150203511-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | CYCS, MT-CO3, CYP4F11 | THRB 649/4885TGFBR1 2707/4885MAPK14 2427/4885 |
| US-20160183529-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | CYP51A1, TCOF1, DDT | THRB 485/4885TGFBR1 615/4885MAPK14 1616/4885 |
| US-20190151299-A1 | BENZOTRIAZOLE-DERIVED ALPHA AND BETA-UNSATURATED AMIDE COMPOUND USED AS TGF-BETA RI INHIBITOR | TGFBR1, TGFBR2, TGFB1 | THRB 76/4885TGFBR1 1/4885MAPK14 785/4885 |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CCL5, IDO1 | THRB 908/4885TGFBR1 493/4885MAPK14 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.